Galapagos Targets Liver Fibrosis With Evotec Deal
Belgium’s Galapagos adds another potential fibrosis drug to its growing pipeline of compounds in a therapeutic area that is also attracting attention from a number of other companies.
You may also be interested in...
Following more promising rheumatoid arthritis data on filgotinib at EULAR, the Belgian biotech's chief medical officer Walid Abi-Saab tells Scrip about the JAK inhibitor's promise in a number of other indications.
Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.
Gilead projects roughly $200m in sales growth for its CAR-T product Yescarta, despite the drug’s modest $6m sequential growth during the fourth quarter. For 2019 overall sales, the company projects slight growth, if any.